Cough Syrup Advisory for Children: Centre Urges Caution After Child Deaths in MP and Rajasthan

The Indian Union Health Ministry has issued a crucial advisory to all States and Union Territories regarding the use of cough syrups in children, following reports of deaths linked to these medications in Madhya Pradesh and Rajasthan. The Directorate General of Health Services (DGHS) emphasizes that cough and cold medicines should not be prescribed or dispensed to children below two years of age and generally not recommended for those under five years. The advisory highlights the self-limiting nature of most acute cough illnesses in children, advocating for cautious use of medications only under strict medical supervision and appropriate dosing.

Key Advisory Details and Background

The DGHS advisory, circulated widely to state health authorities and medical institutions, stresses that most acute coughs in children resolve without pharmacological intervention. Non-pharmacological measures such as adequate hydration, rest, and supportive care are recommended as first-line treatments. Medications, especially cough syrups, should only be used in children above five years after careful clinical evaluation. The advisory further warns against using multiple drug combinations and emphasizes adherence to good manufacturing practices by pharmaceutical companies to avoid substandard or contaminated products.

This advisory follows investigations into child deaths linked to cough syrup use, notably nine fatalities in Madhya Pradesh’s Chhindwara district and two in Rajasthan, with multiple other children affected. Testing of syrup samples by national and state laboratories found no presence of toxic contaminants such as diethylene glycol (DEG) or ethylene glycol (EG), chemicals known to cause acute kidney injury. Despite ruling out these toxins, the link between cough syrups and fatalities has prompted intensified scrutiny and regulatory responses.

Expert Perspectives on Cough Syrup Use in Children

Dr. Monalisa Sahu, Consultant Infectious Diseases at Yashoda Hospitals, Hyderabad, explains that cough syrups provide symptomatic relief but do not treat the underlying cause of cough, which is often viral and self-limiting in children. She emphasizes that many syrups available in India are “irrational” formulations containing multiple drug combinations, increasing the risk of adverse effects without proven benefits. Dr. Sharad Aggarwal, President of the Indian Medical Association (IMA), Delhi, highlights potential side effects including confusion, nausea, skin reactions, and warns against indiscriminate use in young children.

Internationally, bodies such as the U.S. Food and Drug Administration (FDA) recommend against using cough and cold medicines in children under two years due to safety concerns and lack of efficacy. The Indian advisory aligns with such global standards, underscoring the need for judicious prescribing and parental awareness.

Public Health Implications and Practical Advice

The advisory’s emphasis on non-pharmacological care underlines that hydration, rest, and monitoring are often sufficient to manage acute cough symptoms in children. Parents and caregivers are urged to consult healthcare professionals before administering any cough syrups, especially for children under five. Healthcare providers are called upon to avoid prescribing cough medications for very young children and to ensure prescribed products are of verified quality.

Regulatory authorities continue to monitor the quality of cough syrups sold domestically and exported. The Indian government has implemented bans on unapproved fixed-dose combinations including several cough syrups and mandated stringent testing protocols to prevent future incidents.

Limitations and Counterarguments

While no toxic contaminants were found in the syrups linked to recent deaths, the exact causes remain under investigation, underscoring the complexity of medication safety. Some experts note that inappropriate dosing, poor-quality manufacturing, or underlying medical conditions could contribute to adverse outcomes. The advisory hence prioritizes caution over outright bans and advocates balanced clinical judgment and public sensitization to reduce risk.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References